ZEAL Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 891.00 |
| 52 Week High | DKK 972.00 |
| 52 Week Low | DKK 252.60 |
| Beta | 0.64 |
| 11 Month Change | 3.13% |
| 3 Month Change | 45.23% |
| 1 Year Change | 223.06% |
| 33 Year Change | 394.45% |
| 5 Year Change | 575.51% |
| Change since IPO | 1,020.75% |
Recent News & Updates
Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21
Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Recent updates
Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)
Mar 17Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation
Oct 03Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term
Aug 14Some Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14Is Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?
Mar 11What You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition
Jan 12Shareholder Returns
| ZEAL | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -2.1% | 2.5% | -0.3% |
| 1Y | 223.1% | 3.9% | 25.4% |
Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned 8.2% over the past year.
Return vs Market: ZEAL exceeded the Danish Market which returned 27.3% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 9.1% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Volatility Over Time: ZEAL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 288 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | DKK 63.19b |
| Earnings (TTM) | -DKK 712.00m |
| Revenue (TTM) | DKK 367.97m |
171.7x
P/S Ratio-88.8x
P/E RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | DKK 367.97m |
| Cost of Revenue | DKK 714.45m |
| Gross Profit | -DKK 346.47m |
| Other Expenses | DKK 365.53m |
| Earnings | -DKK 712.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -10.04 |
| Gross Margin | -94.16% |
| Net Profit Margin | -193.49% |
| Debt/Equity Ratio | 2.9% |
How did ZEAL perform over the long term?
See historical performance and comparison